Royalty Pharma PLC $RPRX Shares Purchased by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL raised its position in Royalty Pharma PLC (NASDAQ:RPRX) by 34.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 863,835 shares of the biopharmaceutical company’s stock after purchasing an additional 221,099 shares during the period. Tudor Investment Corp ET AL owned about 0.15% of Royalty Pharma worth $30,476,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in RPRX. Royal Bank of Canada boosted its position in shares of Royalty Pharma by 367.7% in the 1st quarter. Royal Bank of Canada now owns 203,760 shares of the biopharmaceutical company’s stock worth $6,342,000 after buying an additional 160,191 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Royalty Pharma by 20.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,990 shares of the biopharmaceutical company’s stock worth $2,490,000 after acquiring an additional 13,489 shares during the last quarter. Focus Partners Wealth purchased a new stake in shares of Royalty Pharma in the first quarter valued at about $264,000. Intech Investment Management LLC lifted its holdings in shares of Royalty Pharma by 41.0% in the first quarter. Intech Investment Management LLC now owns 47,992 shares of the biopharmaceutical company’s stock valued at $1,494,000 after purchasing an additional 13,951 shares in the last quarter. Finally, Savant Capital LLC acquired a new stake in shares of Royalty Pharma in the second quarter valued at approximately $255,000. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Insider Buying and Selling at Royalty Pharma

In other Royalty Pharma news, EVP Marshall Urist sold 20,000 shares of the business’s stock in a transaction dated Friday, January 30th. The stock was sold at an average price of $41.09, for a total transaction of $821,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Terrance P. Coyne sold 34,791 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $46.78, for a total value of $1,627,522.98. Following the sale, the chief financial officer owned 45,761 shares of the company’s stock, valued at $2,140,699.58. This represents a 43.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 517,496 shares of company stock valued at $21,418,283 over the last three months. Corporate insiders own 18.90% of the company’s stock.

Royalty Pharma Trading Down 0.6%

NASDAQ RPRX opened at $45.53 on Friday. The company has a market cap of $26.26 billion, a P/E ratio of 33.73 and a beta of 0.40. Royalty Pharma PLC has a 12 month low of $29.66 and a 12 month high of $47.86. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.40 and a quick ratio of 2.40. The company has a 50-day moving average of $43.68 and a 200-day moving average of $39.81.

Royalty Pharma (NASDAQ:RPRX) last released its earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.33 by $0.13. Royalty Pharma had a net margin of 32.38% and a return on equity of 28.21%. The business had revenue of $621.99 million for the quarter, compared to analysts’ expectations of $839.97 million. As a group, equities analysts predict that Royalty Pharma PLC will post 4.49 earnings per share for the current year.

Royalty Pharma Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Friday, February 20th were paid a dividend of $0.235 per share. The ex-dividend date of this dividend was Friday, February 20th. This represents a $0.94 annualized dividend and a dividend yield of 2.1%. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.22. Royalty Pharma’s dividend payout ratio is presently 69.63%.

Wall Street Analyst Weigh In

RPRX has been the subject of several research reports. The Goldman Sachs Group restated a “buy” rating on shares of Royalty Pharma in a research report on Thursday, February 12th. Wall Street Zen cut Royalty Pharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. Morgan Stanley reissued an “overweight” rating and issued a $61.00 price target on shares of Royalty Pharma in a report on Thursday, February 12th. UBS Group upgraded Royalty Pharma from a “neutral” rating to a “buy” rating and set a $49.00 price objective on the stock in a research report on Friday, January 30th. Finally, Leerink Partners set a $45.00 price objective on Royalty Pharma in a research report on Thursday, December 11th. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Royalty Pharma presently has a consensus rating of “Buy” and a consensus price target of $48.67.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.